Key facts
- It has raised $14.5M; the latest was Accelerator/Incubator ($10K) in Jan 2025.
- Notable investors include MedTech Innovator, Texas Medical Center, SEEDS Capital, Canopus Advisors, 53B — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Biorithm
- ·The full record, as it builds
Funding rounds
No funding rounds for Biorithm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biorithm
Developer of an obstetrics remote monitoring platform and point-of-care devices designed to provide risk-based home care for prenatal and postnatal patients. The company combines advanced proprietary data analytics software and medical-grade wearable for accurate monitoring of a wide range of pregnancy vital data like fetal heart rate, uterine contractions, and maternal heart rate, enabling clinicians to gain new insights into the health of the mother and baby whilst offering expecting mothers' better access to healthcare, convenience, and more information about their pregnancy to identify early signs of complications.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2014
- Employees
- 14
- Website
- bio-rithm.com/
- Ownership
- Privately Held (backing)
Biorithm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biorithm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biorithm in its N-PORT filings yet. We sweep new filings monthly.